KZR - Kezar Life Sciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Kezar Life Sciences, Inc.

4000 Shoreline Court
Suite 300
South San Francisco, CA 94080
United States

Full Time Employees24

Key Executives

NameTitlePayExercisedYear Born
Dr. Christopher J. KirkCo-Founder, Pres, Chief Scientific Officer & Director514.57kN/A1972
Mr. John Franklin FowlerCo-Founder, CEO & DirectorN/AN/A1972
Dr. Jack TauntonCo-FounderN/AN/AN/A
Mr. Marc L. BelskyCFO & Sec.N/AN/A1955
Michael WolfeDirector of Fin. & OperationsN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis. The company was founded in 2015 and is headquartered in South San Francisco, California.

Corporate Governance

Kezar Life Sciences, Inc.’s ISS Governance QualityScore as of February 3, 2020 is 9. The pillar scores are Audit: 3; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.